Strategic partnerships Prevencio has a track record of collaborating with healthcare institutions and health systems (Seattle Children’s, Quadrant Health, MGH) to integrate AI-driven cardiovascular tests, signaling strong sales potential through enterprise partnerships with hospitals, primary care networks, and integrated delivery organizations.

AI driven tests The company emphasizes AI-powered multi-proteomic cardiovascular tests (HART CVE, HART CADhs) with higher accuracy than standard methods, indicating opportunities to upsell to clinics seeking advanced diagnostic tools and to monetize through value-based care pricing tied to improved outcomes.

Market expansion Recent press on partnerships and continued development of tests for pediatric Kawasaki disease and cardiometabolic risk suggests paths to expand into pediatrics, primary care, and cardiology specialty clinics, broadening the addressable market beyond adult cardiology.

Financial levers With revenue in the low millions and an $11M funding base, there is room to pursue channel partnerships, contract manufacturing, and co-development deals with larger diagnostics players seeking AI-enabled blood-based tests to accelerate portfolio diversification.

Competitive positioning Prevencio’s proprietary algorithms, validated in top-tier journals and major meetings, can be packaged as differentiators for enterprise sales to health systems seeking precision risk assessment and preventive cardiology solutions, enabling joint marketing with KOLs and hospital networks.